Lonza Group (XSWX:LONN) FCF Margin % : 2.80% (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Lonza Group FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lonza Group's Free Cash Flow for the six months ended in Dec. 2023 was CHF102 Mil. Lonza Group's Revenue for the six months ended in Dec. 2023 was CHF3,639 Mil. Therefore, Lonza Group's FCF Margin % for the quarter that ended in Dec. 2023 was 2.80%.

As of today, Lonza Group's current FCF Yield % is -0.78%.

The historical rank and industry rank for Lonza Group's FCF Margin % or its related term are showing as below:

XSWX:LONN' s FCF Margin % Range Over the Past 10 Years
Min: -13.69 Med: 6.29 Max: 12.54
Current: -4.38

During the past 13 years, the highest FCF Margin % of Lonza Group was 12.54%. The lowest was -13.69%. And the median was 6.29%.

XSWX:LONN's FCF Margin % is ranked better than
56.76% of 222 companies
in the Medical Diagnostics & Research industry
Industry Median: -10.405 vs XSWX:LONN: -4.38

Lonza Group FCF Margin % Historical Data

The historical data trend for Lonza Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lonza Group FCF Margin % Chart

Lonza Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

4.25

3.48

-2.29

-13.69

-4.38

Lonza Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-5.48	-18.14	-9.60	-12.87	2.80

Competitive Comparison of Lonza Group's FCF Margin %

For the Diagnostics & Research subindustry, Lonza Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lonza Group's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lonza Group's FCF Margin % falls into.

Lonza Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lonza Group's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-294	/	6717
	=	-4.38 %

Lonza Group's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	102	/	3639
	=	2.80 %

Lonza Group FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lonza Group's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lonza Group (XSWX:LONN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lonza Group Ltd (XSWX:LONN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

LZAGY:USA LZAGF:USA LONN:Mexico LONNz:UK LO3A:Germany LONNE:Switzerland

Address

Muenchensteinerstrasse 38, Basel, CHE, CH-4002

Website

https://www.lonza.com

Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.

Lonza Group (XSWX:LONN) Headlines

No Headlines